AUS
NZ
UK
CA
USA
IND
Neurotech International Limited (ASX:NTI), a clinical-stage biopharmaceutical company focused on cannabinoid therapies for paediatric neurological disorders, has completed the issuance of ordinary fully paid shares without investor disclosure by utilising relief provisions under the Corporations Act. On 21 July 2026, the company confirmed compliance with Chapter 2M and related sections of the Act in a notice accompanying an Appendix 2A released the same day.
Key Highlights
- Neurotech International Limited (ASX:NTI) specialises in developing treatments for paediatric neurological disorders.
- On 21 July 2026, the company issued ordinary fully paid shares under section 708A(5)(e) of the Corporations Act 2001 (Cth).
- Shares were issued without disclosure under Part 6D.2 of the Act, leveraging available relief provisions.
- Compliance with Chapter 2M and sections 674 and 674A of the Corporations Act was confirmed as of the notice date.
- No "excluded information" as defined under section 708A(7) of the Corporations Act was identified.
- Neurotech’s lead candidate, NTI164, has successfully completed Phase II/III trials in Autism Spectrum Disorder with statistically significant outcomes.
Neurotech's NTI164 Cannabinoid Therapy and Clinical Pipeline Progress
Neurotech International Limited is advancing NTI164, a broad-spectrum oral cannabinoid therapy targeting paediatric neurological conditions. NTI164 has completed a Phase II/III randomised, double-blind, placebo-controlled clinical trial in Autism Spectrum Disorder (ASD), demonstrating clinically meaningful and statistically significant improvements across validated measures, alongside an excellent safety profile.
Beyond ASD, Neurotech has reported statistically significant Phase I/II trial results in ASD, Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS), Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS), and Rett Syndrome. These outcomes highlight NTI164’s broad therapeutic potential across multiple rare paediatric neurological disorders. The company has also secured human ethics committee approval for a Phase III ASD clinical study, marking advancement toward late-stage development.
Share Issuance Under Section 708A Relief of the Corporations Act
On 21 July 2026, Neurotech International issued ordinary fully paid shares without disclosure documentation, utilising the relief provisions under section 708A(5)(e) of the Corporations Act 2001 (Cth). Details of the issuance, including share quantity and consideration, were disclosed in an Appendix 2A released concurrently with the secondary trading notice.
This mechanism allows companies meeting statutory conditions to issue securities without preparing a disclosure document, facilitating efficient capital raising while ensuring regulatory compliance. Neurotech’s announcement aligns with ASX requirements to inform the market of capital management activities despite the exemption from full disclosure obligations.
Regulatory Compliance and Excluded Information Review
Neurotech confirmed full compliance with Chapter 2M, as well as sections 674 and 674A of the Corporations Act, which govern financial reporting and corporate governance disclosures. The company also assessed the existence of any "excluded information" as per section 708A(7) and reported none, supporting the validity of its reliance on the relief provisions for this share issuance.
Focus on Addressing Unmet Needs in Paediatric Neurological Disorders
Neurotech targets significant unmet clinical needs in paediatric neurological disorders such as Autism Spectrum Disorder, which affects a large global paediatric population and currently lacks disease-modifying treatments. The successful Phase II/III trial results for NTI164 in ASD, coupled with ethics clearance for Phase III studies, underscore the company’s progress toward potential regulatory approval.
Additional focus areas include PANDAS, PANS, and Rett Syndrome—conditions with limited therapeutic options. By developing NTI164 as a single cannabinoid-based platform with efficacy across multiple indications, Neurotech aims to provide a differentiated treatment approach offering safety, tolerability, and efficacy advantages.
Impact of Share Issuance on Capital Structure and Funding
The recent share issuance modifies Neurotech’s capital structure and equity base. While specific issuance details were not disclosed in the announcement, the transaction complies with statutory relief provisions and was transparently communicated via a secondary trading notice consistent with ASX listing rules.
Investors should note potential effects on shareholding percentages and earnings per share. The capital raised is expected to support ongoing clinical development, including the Phase III ASD trial, and general corporate activities.
Clinical Trial Results and Therapeutic Promise of NTI164
The Phase II/III ASD trial, designed as a combined pivotal study, demonstrated clinically meaningful and statistically significant benefits, indicating a strong efficacy signal. The excellent safety profile is especially important given the paediatric population and cannabinoid-based nature of NTI164.
Ethics committee approval for the Phase III ASD trial confirms regulatory confidence in the trial design and safety data, paving the way for patient enrolment in this critical study.
Competitive Position in Paediatric Neurological Therapeutics
Operating within the capital-intensive and highly regulated paediatric neurological therapeutics sector, Neurotech’s cannabinoid-based platform offers a unique approach amid competition from both large pharmaceutical firms and smaller biotech companies. Its clinical-stage status with advanced trial data positions it favorably between early discovery and commercial-stage entities.
Despite promising progress, Neurotech faces typical drug development risks including regulatory approvals, intellectual property challenges, and commercialisation hurdles.
Regulatory Outlook and Upcoming Clinical Milestones
With human ethics committee clearance secured, Neurotech’s next key milestone is initiating the Phase III ASD trial, a large-scale study designed to confirm efficacy and safety. Successful completion will support regulatory submissions to agencies such as the Therapeutic Goods Administration in Australia and counterparts internationally.
The evolving regulatory landscape for paediatric cannabinoid therapeutics presents both challenges and opportunities. Neurotech’s demonstrated efficacy and safety data position it well for ongoing regulatory engagement and potential approval.
Risks in Paediatric Drug Development and Regulatory Approval
Developing drugs for paediatric populations entails stringent safety requirements and complex trial designs due to developmental and pharmacological variability. Regulatory scrutiny is intense, potentially extending timelines and increasing costs.
Additionally, cannabinoid-based therapies face variable regulatory frameworks globally, with shifting policies that could impact development and commercialisation. Neurotech must navigate these evolving environments alongside the inherent uncertainties of clinical development.
